Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab

Ferris, 2016, Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, N. Engl. J. Med., 375, 1856, 10.1056/NEJMoa1602252 Burtness, 2019, Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study, Lancet., 394, 1915, 10.1016/S0140-6736(19)32591-7 Wagner, 2023, Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer, Anticancer. Res., 43, 1273, 10.21873/anticanres.16274 Zhai, 2017, Radiation-induced hypothyroidism after IMRT for nasopharyngeal carcinoma: Clinical and dosimetric predictors in a prospective cohort study, Oral. Oncol., 68, 44, 10.1016/j.oraloncology.2017.03.005 O'Meara, 2003, Follow-up of head and neck cancer patients post-radiotherapy, Radiother. Oncol., 66, 323, 10.1016/S0167-8140(02)00405-X Baghel, 2020, Is thyroid excision mandatory with laryngectomy in carcinoma larynx?, BMC. Cancer., 20, 700, 10.1186/s12885-020-07205-5 Nelson, 2006, Association between development of hypothyroidism and improved survival in patients with head and neck cancer, Arch. Otolaryngol. Head. Neck. Surg., 132, 1041, 10.1001/archotol.132.10.1041 Smith, 2009, Hypothyroidism in older patients with head and neck cancer after treatment with radiation: a population-based study, Head. Neck., 31, 1031, 10.1002/hed.21066 Yasar, 2014, Can non-thyroid illness syndrome predict mortality in lung cancer patients? A prospective cohort study, Horm. Cancer., 5, 240, 10.1007/s12672-014-0183-0 Cengiz, 2008, Nutritional and prognostic significance of sick euthyroid syndrome in non-small cell lung cancer patients, Intern. Med., 47, 211, 10.2169/internalmedicine.47.0423 Gao, 2018, Low T3 syndrome as a predictor of poor prognosis in chronic lymphocytic leukemia, Int. J. Cancer., 143, 466, 10.1002/ijc.31327 Pan, 2022, The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study, Technol. Cancer. Res. Treat., 21, 10.1177/15330338221094422 Economopoulou, 2020, Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab, Oral. Oncol., 111, 10.1016/j.oraloncology.2020.105013 Osorio, 2017, Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer, Ann. Oncol., 28, 583, 10.1093/annonc/mdw640 Sakakida, 2019, Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade, Oncol. Lett., 18, 2140 Yamauchi, 2019, Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab, PLoS. One., 14, e0216954, 10.1371/journal.pone.0216954 Zhou, 2021, Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer, Int. Immunopharmacol., 91, 10.1016/j.intimp.2020.107296 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer., 45, 228, 10.1016/j.ejca.2008.10.026 Harrington, 2023, Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study, J. Clin. Oncol., 41, 790, 10.1200/JCO.21.02508 Cohen, 2019, Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study, Lancet., 393, 156, 10.1016/S0140-6736(18)31999-8 von Itzstein, 2022, Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors, Cancer. Immunol. Immunother., 71, 2169, 10.1007/s00262-022-03151-2 Fliers, 2021, An update on non-thyroidal illness syndrome, J. Endocrinol. Invest., 44, 1597, 10.1007/s40618-020-01482-4 Hoermann, 2022, Principles of Endocrine Regulation: Reconciling Tensions Between Robustness in Performance and Adaptation to Change, Front. Endocrinol. (Lausanne)., 13, 10.3389/fendo.2022.825107 Tognini, 2010, Non-thyroidal illness syndrome and short-term survival in a hospitalised older population, Age. Ageing., 39, 46, 10.1093/ageing/afp197 Kim, 2022, The Tri-iodothyronine (T3) Level Is a Prognostic Factor for Patients With Advanced NSCLC: Receiving Immune Checkpoint Inhibitors and Is Associated With Liver Metastasis, Clin. Med. Insights. Oncol., 16, 10.1177/11795549221139522 Gao, 2017, Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma, Br. J. Haematol., 177, 95, 10.1111/bjh.14528 Xue, 2023, Low T3 syndrome as a predictor of poor outcomes in patients with follicular lymphoma, Ann. Hematol., 102, 851, 10.1007/s00277-023-05117-5 Green, 2020, Emerging immune checkpoint inhibitors for the treatment of head and neck cancers, Expert. Opin. Emerg. Drugs., 25, 501, 10.1080/14728214.2020.1852215 Roussot, 2022, Tumor Immunogenic Cell Death as a Mediator of Intratumor CD8 T-Cell Recruitment, Cells., 11, 10.3390/cells11223672 Welters, 2018, Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer, Clin. Cancer. Res., 24, 634, 10.1158/1078-0432.CCR-17-2140 Wondergem, 2020, The Immune Microenvironment in Head and Neck Squamous Cell Carcinoma: on Subsets and Subsites, Curr. Oncol. Rep., 22, 81, 10.1007/s11912-020-00938-3 Alamino, 2019, Dendritic Cells Exposed to Triiodothyronine Deliver Pro-Inflammatory Signals and Amplify IL-17-Driven Immune Responses, Cell. Physiol. Biochem., 52, 354, 10.33594/000000025 Florencia Soler, 2022, Triiodothyronine-stimulated dendritic cell vaccination boosts antitumor immunity against murine colon cancer, Int. Immunopharmacol., 110, 10.1016/j.intimp.2022.109016 Rubingh, 2020, The Role of Thyroid Hormone in the Innate and Adaptive Immune Response during Infection, Compr. Physiol., 10, 1277, 10.1002/cphy.c200003 Matsuo, 2020, Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab, Oral. Oncol., 101, 10.1016/j.oraloncology.2019.104525 Haas, 2023, The Geriatric Nutritional Risk Index (GNRI) as a Prognostic Biomarker for Immune Checkpoint Inhibitor Response in Recurrent and/or Metastatic Head and Neck Cancer, Nutrients., 15, 10.3390/nu15040880 Mazarico, 2019, Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors, J. Endocrinol. Invest., 42, 1443, 10.1007/s40618-019-01058-x Delivanis, 2017, Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms, J. Clin. Endocrinol. Metab., 102, 2770, 10.1210/jc.2017-00448 Chilelli, 2022, Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival, Cancer. Diagn. Progn., 2, 55, 10.21873/cdp.10076 Thuillier, 2021, Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study, Cancer. Immunol. Immunother., 70, 2023, 10.1007/s00262-020-02802-6 de Filette, 2016, Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab, J. Clin. Endocrinol. Metab., 101, 4431, 10.1210/jc.2016-2300 Fidilio, 2021, Thyroid disorders associated with immune control point inhibitors, Endocrinol. Diabetes Nutr. (Engl. Ed)., 68, 408 Kotwal, 2020, PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients, Thyroid., 30, 177, 10.1089/thy.2019.0250